Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Yahoo! Finance
LONDON, February 27, 2025 BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditions where we believe we can deliver on clear unmet needs with first-in-class and/or best-in-class siRNAs. We believe divesiran is a great example of this strategy and clinical commitment. We are pleased to announce today that we anticipate full enrollment in the SANRECO Phase 2 study of divesiran in PV by year-end. While we remain confident in our zerlasiran program for high Lp(a), we wil
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- With 35% ownership, Silence Therapeutics plc (NASDAQ:SLN) insiders have a lot at stake [Yahoo! Finance]Yahoo! Finance
- TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
- TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of GrowthBusiness Wire
- Silence Therapeutics CEO Craig Tooman steps down [Seeking Alpha]Seeking Alpha
- Silence Therapeutics Announces Leadership Changes [Yahoo! Finance]Yahoo! Finance
SLN
Sec Filings
- 12/22/25 - Form 4
- 12/22/25 - Form 4
- 12/22/25 - Form 3
- SLN's page on the SEC website